Literature DB >> 15855008

Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model.

A Phelps1, A J Gates, M Hillier, L Eastaugh, D O Ulaeto.   

Abstract

There is currently considerable concern about the vulnerability of human populations to biowarfare or bioterrorist attacks with variola virus (VARV). Traditional smallpox vaccines were manufactured using the lymph of ruminants infected with the vaccinia virus (VACV). However, these production methods do not meet current standards for vaccines, especially since the emergence of transmissable spongiform encephalopathies in domesticated ruminants. This study has examined the protective efficacy of the Lister (Elstree) vaccine strain from various sources in a murine lethal challenge model. Considerable variation in efficacy is observed between the Lister material obtained from the American Type Culture Collection (ATCC) and the same strain obtained from vaccine stockpiles. A new, tissue-culture derived Lister vaccine is assessed against a bench-mark of multiple lots from a historical stockpile of the traditional vaccine. Apparent qualitative differences are observed between historical and new vaccines. Statistically significant differences are observed between different batches of the traditional vaccine, and the efficacy of the tissue-culture produced vaccine falls within this range.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855008     DOI: 10.1016/j.vaccine.2005.02.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Protective properties of vaccinia virus-based vaccines: skin scarification promotes a nonspecific immune response that protects against orthopoxvirus disease.

Authors:  Amanda D Rice; Mathew M Adams; Scott F Lindsey; Daniele M Swetnam; Brandi R Manning; Andrew J Smith; Andrew M Burrage; Greg Wallace; Amy L MacNeill; Richard W Moyer
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

2.  Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.

Authors:  Natalie J Thornburg; Caroline A Ray; Martha L Collier; Hua-Xin Liao; David J Pickup; Robert E Johnston
Journal:  Virology       Date:  2007-02-09       Impact factor: 3.616

3.  Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.

Authors:  D Huw Davies; Linda S Wyatt; Frances K Newman; Patricia L Earl; Sookhee Chun; Jenny E Hernandez; Douglas M Molina; Siddiqua Hirst; Bernard Moss; Sharon E Frey; Philip L Felgner
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

4.  Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.

Authors:  Mathew M Adams; Amanda D Rice; R W Moyer
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

5.  Emergence and reemergence of vaccinia-like viruses: global scenario and perspectives.

Authors:  R K Singh; V Balamurugan; V Bhanuprakash; G Venkatesan; M Hosamani
Journal:  Indian J Virol       Date:  2012-04-04

6.  Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.

Authors:  Sarah Reeman; Amanda J Gates; David J Pulford; Art Krieg; David O Ulaeto
Journal:  Viruses       Date:  2017-12-09       Impact factor: 5.048

7.  Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus.

Authors:  Anuja Mathew; Joel O'Bryan; William Marshall; Girish J Kotwal; Masanori Terajima; Sharone Green; Alan L Rothman; Francis A Ennis
Journal:  PLoS One       Date:  2008-10-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.